Designation of Idebenone (Raxone) as an orphan drug - TudorRose Consulting Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods in Australia, ensuring that these products are safe, of high quality, and effective for their intended use. This Act was introduced to address the need for a comprehensive regulatory framework governing the manufacturing, importation, supply, and advertising of therapeutic goods, which include medicines, medical devices, blood, and tissues. The Therapeutic Goods Administration (TGA), operating under the auspices of the Australian Government's Department of Health, is the body responsible for administering this Act. The primary policy objective of the Act is to protect and enhance public health by regulating the therapeutic goods market, thereby ensuring that consumers and healthcare professionals have access to safe and effective therapeutic goods. The designation of idebenone (Raxone) as an orphan drug for the treatment of Duchenne muscular dystrophy, as announced on 24 August 2016 by Dr Anthony Gill, the Delegate of the Secretary, exemplifies the Act's role in facilitating access to treatments for rare diseases.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration under the Commonwealth of Australia, applies to therapeutic goods, including medicines, medical devices, and related substances. The Act encompasses a broad range of entities, including manufacturers, importers, and suppliers of therapeutic goods, ensuring these entities adhere to specified standards and regulations to safeguard public health. The geographic reach of the Act is national, extending across Australia, including its territories, and it applies to all therapeutic goods intended for use within its jurisdiction. The Act includes mechanisms for designating certain medicines, such as orphan drugs, which are those intended for the treatment of rare medical conditions. In this instance, idebenone (Raxone) has been designated as an orphan drug for the treatment of Duchenne muscular dystrophy. This specific designation is subject to the Therapeutic Goods Regulations 1990, which allow for the classification and regulation of therapeutic goods through subordinate instruments. While the Act provides comprehensive coverage, there are certain exclusions and exemptions, typically defined through regulations and specific provisions within the Act. These may include exemptions for small-scale or research-based activities that do not pose significant risk to public health.

Key Provisions

The Therapeutic Goods Act 1989 (section 16J) and the Therapeutic Goods Regulations 1990 (subregulation 16J(2)) provide the framework for the designation of orphan drugs. In this instance, idebenone (Raxone) has been designated as an orphan drug for the treatment of Duchenne muscular dystrophy, effective from 24 August 2016 (section 16J). This designation recognises idebenone's potential in treating a rare condition that affects a small population, thus encouraging its development and availability. The specific form of the drug designated is a film-coated tablet, indicating the approved method of administration for this therapeutic purpose. Entities and individuals governed by this Act are subject to certain obligations and requirements. The sponsor of the orphan drug, in this case, TudorRose Consulting Pty Ltd, must ensure that the drug meets the standards set out in the Therapeutic Goods Act 1989 and the Regulations. This includes compliance with quality, safety, and efficacy requirements, as well as proper labelling and advertising practices. The sponsor is also responsible for maintaining records and providing information as required by the Therapeutic Goods Administration (TGA). Failure to comply with the provisions of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in various civil and criminal consequences. For instance, if the sponsor fails to adhere to the quality and safety standards, the TGA may take enforcement actions such as recalls, fines, or prosecutions. Under section 26 of the Act, offences can result in substantial penalties. For example, corporations can be fined up to $2,100,000, while individuals can face fines of up to $210,000 and imprisonment for up to five years. These penalties underscore the importance of strict compliance with the legislative and regulatory requirements.